Treatment with parthenolide, a p65‐specific inhibitor, disinhibited the expression of miR‐23a (Figure 3D), whereas significantly decreased phosphorylated form of p65 and CCL22 protein and mRNA levels in both tumor cell lines (Figure 3E‐G). Here, CCL22 is linked to neoplasm.